Use of Bevacizumab (Avastin) in the Treatment of Metastatic Breast Cancer

Does Not Meet CTAF Criteria

This topic was reviewed by the California Technology Assessment Forum on June 18, 2008.

It is recommended that the use of bevacizumab as initial or second-line treatment for metastatic breast cancer does not meet CTAF Technology Assessment Criteria 3 through 5 for safety, effectiveness and improvement in health outcomes.


Full Assessment:

Download (PDF, 226 KB)

Search Assessments

Email Notification

Sign up to receive email notifications of upcoming CTAF meetings and new assessments.

 

Methodology

Learn about the CTAF criteria used to evaluate a new or emerging technology.

Criteria used »
Assessment Process »
Format of Report »

Suggest an Assessment

Know of a new device, procedure, or test that CTAF should consider for assessment?

Contact us »
 
© 2008 California Technology Assessment Forum. All rights reserved.

Contact Us | Privacy Policy | Terms of Use | Credits